IMNM vs. ABVX, ETNB, SPRY, OPK, CNTA, PLRX, LQDA, ZNTL, OCUL, and ARQT
Should you be buying Immunome stock or one of its competitors? The main competitors of Immunome include ABIVAX Société Anonyme (ABVX), 89bio (ETNB), ARS Pharmaceuticals (SPRY), OPKO Health (OPK), Centessa Pharmaceuticals (CNTA), Pliant Therapeutics (PLRX), Liquidia (LQDA), Zentalis Pharmaceuticals (ZNTL), Ocular Therapeutix (OCUL), and Arcutis Biotherapeutics (ARQT). These companies are all part of the "pharmaceutical preparations" industry.
ABIVAX Société Anonyme (NASDAQ:ABVX) and Immunome (NASDAQ:IMNM) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership, analyst recommendations and community ranking.
Immunome received 20 more outperform votes than ABIVAX Société Anonyme when rated by MarketBeat users. Likewise, 68.57% of users gave Immunome an outperform vote while only 66.67% of users gave ABIVAX Société Anonyme an outperform vote.
ABIVAX Société Anonyme has higher earnings, but lower revenue than Immunome.
ABIVAX Société Anonyme has a net margin of 0.00% compared to ABIVAX Société Anonyme's net margin of -1,829.44%. Immunome's return on equity of 0.00% beat ABIVAX Société Anonyme's return on equity.
47.9% of ABIVAX Société Anonyme shares are held by institutional investors. Comparatively, 44.6% of Immunome shares are held by institutional investors. 20.0% of Immunome shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
ABIVAX Société Anonyme presently has a consensus price target of $32.00, suggesting a potential upside of 134.60%. Immunome has a consensus price target of $30.50, suggesting a potential upside of 120.54%. Given Immunome's higher probable upside, equities research analysts plainly believe ABIVAX Société Anonyme is more favorable than Immunome.
In the previous week, Immunome had 28 more articles in the media than ABIVAX Société Anonyme. MarketBeat recorded 28 mentions for Immunome and 0 mentions for ABIVAX Société Anonyme. ABIVAX Société Anonyme's average media sentiment score of 0.38 beat Immunome's score of 0.00 indicating that Immunome is being referred to more favorably in the news media.
Summary
Immunome beats ABIVAX Société Anonyme on 8 of the 13 factors compared between the two stocks.
Get Immunome News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMNM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Immunome Competitors List
Related Companies and Tools
